Monument Therapeutics
Cambridge
About Monument Therapeutics
Monument Therapeutics is a UK-based private clinical stage drug development company. It uses proprietary digital biomarkers to apply a stratified medicine approach to psychiatry and neurology . Lead asset MT1988 is currently in phase 2 for cognitive impairment in schizophrenia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $7.9M
- Last round: Series Unknown (Feb 2026)
- Website: monumenttx.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/monument-therapeutics-22258 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.